Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 5Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Pancreatic Neoplasms 2Melanoma 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Sarcoma, Ewing 1SCLC 1Retinoblastoma 1Osteosarcoma 1Oligometastatic Disease 1Neoplasms, Germ Cell and Embryonal 1Nasopharyngeal Carcinoma 1NSCLC 1Mouth Neoplasms 1Lymphoma, Follicular 1Lymphoma 1Locally Advanced Resectable Rectal Cancer 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1

Interventions

Gemcitabine 5Cisplatin 5Oxaliplatin 2pertuzumab 1durvalumab 1Trastuzumab 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Lymph Node Excision 1Laparoscopy 1Geriatric Assessment 1Everolimus 1Drug Therapy 1Chemoradiotherapy 1Capecitabine 1ARRY-334543 1130-nm albumin-bound paclitaxel 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Gallbladder Neoplasms × Drug Therapy × Clear all
NCT05833815 2024-08-13

Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

Banaras Hindu University

Phase 2/3 Recruiting
56 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡